

Conducting sustainable growth



Overview

- 3 Sustainability at Hansa Biopharma
- 4 CEO's letter
- 5 Sustainability strategy
- 6 Sustainability Strategy 1: Healthy People
- 8 Sustainability Strategy 2: Healthy Business
- 10 Sustainability Strategy 3: Healthy People

Hansa reports in accordance with the Swedish Annual Accounts Act. The company is currently not within the scope of the Corporate Sustainability Reporting Directive (CSRD). The Company's Annual Report and Sustainability Report were published on 26 March 2026. The Sustainability Report considers the Global Reporting Initiative's (GRI) reporting standard.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This report covers the reporting period for the year ending 31 December 2025. Hansa Biopharma publishes a Sustainability Report every year in line with our annual financial reporting. The Sustainability Report is not externally assured.

Contact:
kerstin.falck@hansabiopharma.com

Welcome

Sustainability at Hansa Biopharma

At Hansa, sustainability is an integral part of how we work and central to achieving the company's long-term goals and vision. We are committed to responsible growth and work continuously with sustainability, ensuring we meet evolving external requirements while staying true to our core values and our scientific and commercial ambitions.

Our priorities are guided by recognized standards, drawing inspiration from the Global Reporting Initiative (GRI), and continuing to evolve our business. In 2024, we carried out our first Double Materiality Assessment, providing valuable insights that inform our focus areas for 2025 and beyond. As our global footprint expands, we also recognize the environmental implications of increased travel, particularly linked to activities in the U.S. market, and remain committed to managing these impacts transparently.

Sustainability at Hansa is not a separate function but a shared mindset, embedded in our culture, shaped by our values, and essential to delivering meaningful, long-term value for patients, society, and shareholders.

64%

of all employees are women
(December 2025)



Zero

cases of unethical
behavior identified



24

countries in 2025 with
reimbursement



100%

renewable energy used at
the Lund headquarters



CEO's letter

Sustainability Report 2025

2025 has been a defining year for Hansa as we continued to advance our vision: *Through pioneering science and collaboration, we enable life-changing outcomes for patients with acute or serious immune-mediated conditions.*

Our progress reflects a strong commitment to expand access to advanced IgG-cleaving therapies for patients in urgent need of desensitization and those living with autoimmune conditions, while operating responsibly and sustainably.

This year, we strengthened the foundation for broader access to IDEFIRIX, further establishing its role in improving outcomes for highly sensitized kidney transplant patients. We supported the wider adoption of standardized desensitization pathways and deepened collaboration with transplant centers. We also advanced clinical development, generating data on the use of imlifidase as a pre-treatment to enable gene therapies for patients with high levels of pre-formed anti-AAV antibodies.

Our submission of a Biologics License Application to the Food and Drug Administration in December marked an important milestone, bringing us closer to potential approval in the United States in 2026. A positive regulatory outcome would unlock access for patients across a major global transplant market and represent a critical step in meeting substantial unmet medical needs for highly sensitized kidney transplant patients.

As we prepare for a potential U.S. launch and engage extensively with investors, travel increased in 2025, an expected consequence of planned market expansion and our commitment to transparent engagement with stakeholders.

Sustainability continues to be embedded in our strategy. Guided by the priorities identified in our 2024 Double Materiality Assessment, we continue to focus on delivering innovative medicines to patients in need while creating value also for shareholders, clinicians, and communities. At our core, we are driven by the urgent needs of patients and guided by our values: Courage, Accountability, Integrity, and Pioneering. These principles ensure that we act decisively, transparently, and ethically as we work to bring transformative medicines to those who need them most.

Looking ahead, we remain committed to responsible growth and to advancing solutions that improve lives.

Renee Aguiar Lucander
CEO Hansa Biopharma AB
Lund, Sweden, March 2026



Our sustainability strategy

The Company's sustainability strategy consists of three focus areas:



Healthy People
addressing
unmet medical
needs

Healthy Business
Based on Hansa's
values: Courage,
Accountability,
Integrity and
Pioneering

Healthy Planet
Embracing
sustainable
decision-making
and environmental
stewardship

Hansa is committed to addressing unmet medical need through pioneering science and collaboration, enabling life changing outcomes for patients with acute or serious immune mediated conditions. Our efforts to develop, commercialize, and provide access for novel immunomodulatory therapies aim to transform care for patients in areas where there are few or no treatment options available.

Hansa's sustainability strategy has a core focus, ensuring that the Company delivers both innovation and value efficiently and sustainably while meeting the expectations of external and internal stakeholders. Hansa aims to act as a responsible business that plays an important role in society and strives to have a positive impact on the communities in which Hansa operates.

**We aim to
transform care
for patients
with unmet
needs.**

Aligning with the UN Sustainable Development Goals



The United Nations' Sustainable Development Goals consists of 17 Sustainable Development Goals (SDGs) that provide a global strategy for tackling poverty, hunger, health, education, inequality, economic growth, climate change, and conservation, by 2030. Hansa has aligned its strategy with these goals, and have identified six SDGs where the Company can positively contribute.

- > Ensure healthy lives and promote well-being for all at all ages
- > Achieve gender equality and empowerment for all women and girls
- > Promote sustained, inclusive, and sustainable economic growth, full and productive employment, and decent work for all
- > Industry, Innovation and Infrastructure
- > Reduce inequalities
- > Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable, and inclusive institutions at all levels.




Sustainability Strategy 1

Healthy People

Hansa's primary contribution to addressing unmet medical needs lies in the development, commercialization, and enablement of access to unique immunomodulatory therapies.

Hansa recognizes that creating meaningful and lasting impact for patients requires a holistic view of the healthcare landscape. Addressing unmet medical needs extends beyond providing access to our therapies; it involves understanding the full continuum of care and the barriers patients face throughout their journey. This perspective guides Hansa's collaborations with stakeholders across the healthcare ecosystem and strengthens our ability to support better outcomes for patients and communities.



Sustainability Strategy 1: Healthy People continued

In 2025, Hansa participated in a wide range of medical events and scientific congresses to share clinical and scientific data, engaged in dialogue with experts, and, where relevant, helped educate clinicians on the unmet needs of highly sensitized kidney transplant patients.

During the year, the Company also advanced its IgG-cleaving enzyme technology across clinical trials in key areas of high unmet medical need, including kidney transplantation, gene therapy and autoimmune diseases, reinforcing the Company's commitment to developing innovative therapies that address critical gaps in care.

Hansa continued its engagement across Europe and the United States with patient advocacy groups, individual patient advocates and policymakers to raise awareness and advance access to new treatment for patient groups with limited or no alternatives.

Throughout 2025, Hansa worked closely with patient organizations to gain deeper insight into the needs and experiences of patients, particularly those awaiting kidney transplantation, ensuring that patient perspectives remain central to the Company's decisions and guide efforts to deliver better outcomes where they are most needed.

Hansa engages with patient groups based on three key partnership principles: independence of patient groups, respect and clarity of purpose of advocates, and transparency in financial support provided. In 2024, the Company formalized principles, creating and implementing a company policy on Interactions with Patient Advocacy Groups ("PAGs"). In 2025 Hansa reviewed the policy on Corporate Giving outlining the standards and principles governing Grants, Donations, Contributions, and Sponsorships provided by Hansa to Healthcare Professional Societies ("HPSs"), PAGs and other organizations including research organizations, academia, and healthcare institutions (e.g., hospitals) engaged directly or indirectly in healthcare and the support of patients. In addition, a standard operating procedure (SOP) on Corporate Giving to PAGs has been implemented to ensure company-wide awareness of a new centralized approach to PAG support.

PAG Name	Short description	Amount	Currency	Approx SEK	Country
American Association of Kidney Patients (AAKP)	Patron level sponsor of 50th Annual National Patient Meeting and Bronze level sponsor of 7th Annual Global Summit on Kidney Disease Innovations	32,000	USD	285,000	USA
Associazione Nazionale Emodializzati (ANED)	Support for ANED round table on 'Kidney transplantation: barriers and new opportunities'	15,000	EUR	159,000	Italy
Bundesverband Niere e.V.	Sponsorship of a webinar on the topic of organ transplantation and follow up report in the Bundesverband Niere e.V. patient magazine	5,000	EUR	54,000	Germany
European Kidney Health Alliance (EKHA)	Silver level corporate membership	25,000	EUR	270,000	Belgium
Federación Nacional de Asociaciones ALCER	Corporate sponsors of the ALCER 'National Congress for Renal People' and sponsorship of a round table discussion by KOLs on HS Kidney Transplant at the ALCER Barcelona Patient Meeting	5,000	EUR	54,000	Spain
Kidney Research UK	Annual membership of Industry Partnership Project	8,000	GBP	104,000	UK
Kidney Research UK	Support for a focus group on Access to Transplantation for HS patients	25,000	EUR	270,000	France
Selbsthilfe Niere	Sponsorship of Selbsthilfe Niere journal through 2026	8,606	EUR	91,000	Austria

Sustainability Strategy 2

Healthy Business

A healthy business is built on strong values, ethical conduct, and a culture where people can thrive. Hansa's values are **Courage, Accountability, Integrity, and Pioneering**, and guide how the Company operates and supports its employees in driving meaningful impact for patients.

These values shape Hansa's decision making, interactions and commitment to acting transparently and responsibly across all parts of the organization.



Sustainability Strategy 2: Healthy Business continued

Hansa continues to strengthen the structures and processes that ensure business operations are conducted ethically and in full compliance with applicable laws and regulations.

Continuous engagement between employees and both the Legal and Compliance function and Quality Assurance ensures that all colleagues remain informed about relevant policies, principles, and procedures. The Legal and Compliance function reports directly to the CEO and plays an active role in the Executive Committee and in supporting the Board of Directors, reinforcing accountability and governance at the highest level.

The Company's **Code of Conduct** remains a foundational reference for expected behaviors and business practices. It provides clear guidance on topics including anti corruption, medical ethics, responsible interactions with external stakeholders, diversity and inclusion, supplier selection, and sustainability expectations. Regular training ensures that employees understand these standards and apply them consistently in their work.

Hansa's focus on healthy business is inseparable from the Company's focus on healthy people. By fostering an inclusive, respectful, and collaborative culture grounded in Hansa's values, Hansa ensures that employees feel empowered to contribute, innovate, and uphold the highest ethical standards. This foundation enables Hansa to deliver long term, sustainable value for patients, society, and shareholders.

Sustainability governance at Hansa

Hansa's Board of Directors acts as the highest governance body and is responsible for the approval of the overall business strategy including sustainability, company policies and the Code of Conduct.

Sustainability Strategy 3

Healthy Planet

Embracing Sustainable Decision Making and Environmental Stewardship. Throughout 2025, Hansa continued to embed sustainable decision making into its operations, reflecting the Company's commitment to responsible environmental stewardship.

In line with the sustainability strategy and environmental principles, we remain focused on keeping the Company's environmental footprint at a low level while supporting the Company's broader scientific and commercial growth.



Sustainability Strategy 3: Healthy Planet continued

During the year, 100% of the energy used for the Lund headquarters was sourced from renewable energy, primarily hydroelectric power, an important step in reducing our operational emissions.

Wastewater generated at our sites continued to be managed in accordance with local regulations and reported to the appropriate authorities. All waste was sorted and handled as required by local waste management standards, underscoring our commitment to recycling and reuse in line with compliant and responsible operations.

This year's report reflects a decrease in the Company's overall environmental footprint. At the same time, business travels increased, primarily due to preparations for a potential U.S. launch and extensive engagement with investors and external stakeholders, an expected development aligned with our expanding global footprint and strategic ambitions.

As the Company continues to grow, Hansa remains committed to identifying opportunities to reduce environmental impact across the value chain. Hansa will continue to integrate sustainability considerations into key business decisions and advance efforts that support a resilient, environmentally responsible organization. This approach ensures that environmental stewardship remains a core component of how Hansa operates today and plans for tomorrow.

Energy consumption in 2025 (tCO₂e)

Electricity (location-based):	3.11
of which renewable	100%
Heating and steam:	5.20
of which renewable	100%
Cooling:	0.34
Total	8.65

Breakdown of scope 3 emissions (tCO₂e) by category

Purchased goods and services	3,999.60
Upstream transportation and distribution	258.65
Capital goods	0.14
Business travel	396.17
Fuel and energy-related activities	4.89
Waste generated in operations	0.00
Total	4,659.45

Emissions (in tCO₂e)

Scope 1 – Mobile combustion	0
Scope 2 – Electricity, Heating, Cooling	8.66
Scope 3 – Value chain	4,659.45
Grand total	4,668.10



Hansa Biopharma AB

P.O. Box 785

SE-220 07 Lund, Sweden

Phone: +46 46 16 56 70

E-mail: info@hansabiopharma.com

www.hansabiopharma.com